Indolo[3,2-
d
][1]benzazepines (paullones), indolo[3,2-
d
][2]benzazepines, and indolo[2,3-
d
][2]benzazepines
(latonduines) are isomeric scaffolds of current medicinal interest.
Herein, we prepared a small library of novel indolo[3,2-
d
][2]benzazepine-derived ligands
HL
1
–
HL
4
and copper(II)
complexes
1
–
4
. All compounds were
characterized by spectroscopic methods (
1
H and
13
C NMR, UV–vis, IR) and electrospray ionization (ESI) mass
spectrometry, while complexes
2
and
3
, in
addition, by X-ray crystallography. Their purity was confirmed by
HPLC coupled with high-resolution ESI mass spectrometry and/or elemental
analysis. The stability of compounds in aqueous solutions in the presence
of DMSO was confirmed by
1
H NMR and UV–vis spectroscopy
measurements. The compounds revealed high antiproliferative activity
in vitro in the breast cancer cell line MDA-MB-231 and hepatocellular
carcinoma cell line LM3 in the low micromolar to nanomolar concentration
range. Important structure–activity relationships were deduced
from the comparison of anticancer activities of
HL
1
–
HL
4
and
1
–
4
with those of structurally
similar paullone-derived (
HL
5
–
HL
7
and
5
–
7
) and latonduine-derived scaffolds (
HL
8
–
HL
11
and
8
–
11
). The high anticancer
activity of the lead drug candidate
4
was linked to reactive
oxygen species and endoplasmic reticulum stress induction, which were
confirmed by fluorescent microscopy and Western blot analysis.